H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals to CHF 28 from CHF 24 and keeps a Buy rating on the shares after the FDA approved Agamree the treatment of Duchenne muscular dystrophy.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>